YH 009
Alternative Names: YH-009Latest Information Update: 28 Dec 2025
At a glance
- Originator Beijing Biocytogen
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 28 Dec 2025 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections in China (Parenteral)
- 28 Dec 2025 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections(Prevention) in China (Parenteral)
- 30 Nov 2021 YH 009 is available for licensing as of 30 Nov 2021. https://biocytogen.com/pipeline/yh009/